RGL-270 / Shanghai Regenelead Therapies - LARVOL DELTA

Safety, efficacy, and immunogenicity of adjuvant therapy with personalized cancer vaccine (PCV) RGL-270 in combination with adebrelimab and mFOLFIRINOX in resectable pancreatic ductal adenocarcinoma (PDAC). (ASCO 2026) - P1 | "Based on proprietary LNP delivery systems, algorithms for neoantigen identification and immunogenicity prediction, the combination treatment of RGL-270 and adebrelimab demonstrated a favorable safety profile, promising efficacy, and robust immunogenicity. This preliminary result guarantees the further development of PCV-based anti-tumor therapy in the adjuvant setting for PDAC."

Clinical • Combination therapy • IO biomarker • Infectious Disease • Influenza • Oncology • Pancreatic Ductal Adenocarcinoma • Respiratory Diseases

RGL-270 + ICI in Advanced NSCLC (clinicaltrials.gov) - P=N/A | N=40 | Recruiting | Sponsor: Guangdong Association of Clinical Trials | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2028 ➔ Dec 2027 | Trial primary completion date: Jun 2027 ➔ Dec 2027

Enrollment open • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

An open-label, multicenter phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, immunogenicity and preliminary efficacy of the personalized neoantigen mRNA vaccine RGL-270 in combination with adebrelimab in patients with advanced solid tumors (ChiCTR) - P1 | N=29 | Sponsor: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; National Cancer Center/Cancer Hospital,

New P1 trial • Oncology • Solid Tumor

An open, multi-center phase I clinical study to evaluate the safety, tolerance, pharmacokinetics and immunogenicity of personalized new antigen RGL-270 single drug and combined with adebelimab in patients at high risk of recurrence after radical treatment of malignant solid tumors (ChiCTR) - P1 | N=198 | Not yet recruiting | Sponsor: Fudan University Shanghai Cancer Center; Shanghai Regenelead Theraples,Co,Ltd.

New P1 trial • Colon Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Hepatocellular Cancer • Lung Cancer • Melanoma • Mucosal Melanoma • Non Small Cell Lung Cancer • Pancreatic Ductal Adenocarcinoma • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor • ALK • BRAF • EGFR